Roche’s study flop marks yet another Alzheimer’s setback
Roche’s study flop marks yet another Alzheimer’s setback June 16, 2022, 9:10 AM EDT By Natalie Grover ZURICH/LONDON, June 16 (Reuters) –
Roche’s study flop marks yet another Alzheimer’s setback June 16, 2022, 9:10 AM EDT By Natalie Grover ZURICH/LONDON, June 16 (Reuters) –
Alzheimer’s-like changes found in COVID patients’ brains; flu shot, mRNA booster safe together February 4, 2022; 4:43 PM EST By Nancy
[Loads of images come up when you google “brain health” or “brain fitness,” but I liked this one much more than all of the ones with brains
Researcher Amir Hirsa has found a way 240 miles above the Earth’s surface to study the aggregation of proteins that are the hallmarks of
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring this time nine scientific reports and industry developments to help promote
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring this time nine scientific reports and industry developments to help promote
I-Mab will launch a Phase 1 clinical trial evaluating Protollin, its nasal spray immunotherapy candidate for Alzheimer’s disease. The biotech
Doctors Blast Biogen Alzheimer Approval as ‘Regulatory Failure’ (Bloomberg): Top researchers who advised the U.S. Food and Drug Administration on
# # # # Over the last decade, a large number of clinical trials involving immunotherapy have been conducted in the field of Alzheimer’s
New Vaccine Formulation Shows Promise for Alzheimer’s Target Published: Feb. 11, 2021 By Mark Terry BioSpace Switzerland-based AC Immune SA
# # # # Air pollution is an international problem in the post-industrial world. Poor air quality has been associated with an increasing number
As the Alzheimer’s disease world continues to closely follow the development of therapies that break up clumps of beta amyloid on patients’
Time for a new edition of SharpBrains’ e-newsletter. #1. First of all, it’s not all bad news this month. Study finds that moderate lifetime
__ Time for a new edition of SharpBrains’ e‑newsletter. #1. First of all, it’s not all bad news this month. Study finds that moderate lifetime
Researchers have discovered a likely reason why the most common form of the CD33 protein is a risk factor for Alzheimer’s disease, a finding that